FDA Looking At Genetic Factors In Vaccine Safety With New Research Group
Executive Summary
FDA's latest target in its genomics research is vaccine safety, with a new effort to investigate how genetics contribute to vaccine reactions. The agency has hired staff and started work on strategic plans for a new, dedicated team within the Center for Biologics Evaluation and Research
You may also be interested in...
Biomarker Guidance To Encompass More Than Biomarkers, FDA Says
The draft guidance for biomarker qualification FDA is developing has taken a turn mid-stream and will focus on an array of drug development tools
FDA Prepares To Begin Search For Drug Safety Issues At Molecular Level
Combination of new science and technology could allow drug developers to identify molecular risk targets, much as they look for therapeutic targets, agency tells advisory panel.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011